Gene editing remains one of biotech’s most important long-duration themes because it combines platform science with the possibility of one-time, potentially curative medicines. What makes the group more investable today than a few years ago is that the story is no longer purely theoretical. The first approved CRISPR-based therapy, CASGEVY, generated $116 million of revenue in 2025 for CRISPR Therapeutics, giving the market a real commercial proof point. That does not remove the sector’s risk, but it does show that gene editing can move beyond preclinical promise and into regulated, reimbursed medicine.
Investors should also think about the space in layers rather than as a single bucket. First are the ex vivo CRISPR/Cas9 pioneers that have already helped establish regulatory precedent. Next are newer editing approaches such as base editing and prime editing, which aim to improve precision and broaden the range of treatable mutations. Finally, delivery matters just as much as the editing tool itself, especially for in vivo programs targeting the liver, blood, cardiovascular disease, and eventually harder-to-reach tissues. The companies on this list span those layers, which is why the theme offers multiple ways to invest in the same scientific shift.
For May 2026, we ranked seven gene editing stocks in countdown order from #7 to #1 based on investment quality, balancing platform strength, commercial validation, financial profile, analyst sentiment, and recent execution. That means the list starts with the most speculative names and works toward the strongest overall pick at the end. In a sector where clinical progress can create sharp winners and losers, the quality of the platform and the resilience of the balance sheet matter almost as much as any single program.
Our screen focused on US-listed gene editing companies with market capitalizations above $500 million, then ranked them by overall investment quality rather than pure upside. We emphasized platform breadth, program maturity, revenue base, profitability trends, earnings execution, and analyst positioning using primary-source financial data and our composite metrics. Because this is a countdown, the companies appear from #7 to #1, with the best overall pick revealed last. In a young biotech segment, that approach favors businesses with stronger validation and more durable strategic positioning over purely early-stage optionality.
What they do. The company is developing genetic medicines built around prime editing, a technology designed to write precise edits without creating a double-stranded DNA break. Its lead therapeutic candidate is PM359 for chronic granulomatous disease in a Phase 1/2 clinical trial, while PM577 for Wilson disease and PM647 for a SERPINA1-related liver disorder are earlier-stage programs. Prime also has vivo liver programs and cystic fibrosis efforts, plus research and licensing relationships with BMS, the Cystic Fibrosis Foundation, Broad Institute, and Beam.
Why it fits. Prime Medicine belongs on a gene editing list because it represents one of the clearest public-market ways to invest in next-generation editing beyond first-wave CRISPR/Cas9. The appeal is the platform’s ambition: if prime editing can deliver precise correction across blood, liver, and pulmonary disease settings, it could eventually support a broader franchise than one-off rare-disease programs. The challenge is that most of that value remains ahead of the company rather than already demonstrated in the numbers.
Numbers that matter. Prime’s market cap is about $507.5 million to $511.1 million in our data, placing it just above the size threshold for this list. Revenue is only $4.034 million, while EBITDA was negative $199.135 million, which helps explain the weak composite quality grade of D+. Revenue declined 41.1% year over year, and trailing EPS was -$1.23, though the next-year EPS estimate improves to -$0.8704. Profitability remains deeply negative, with ROE at -2.1607, ROA at -0.4146, gross margin at -3722.0%, and operating margin at -59.1752.
Recent momentum. Prime has actually executed better on earnings than the low quality grade suggests, beating estimates in 7 of the last 8 quarters. The latest report on May 7, 2026 missed, with EPS of -$0.28 versus a -$0.2487 estimate, a -12.6% surprise, but the prior quarter beat by 6.9% and several earlier beats were larger. Analyst sentiment is cautious rather than outright bullish, with 2 Buy ratings and 4 Hold ratings, and the average target of $6.9167 sits well above where the shares last closed.
What they do. Precision BioSciences is a clinical-stage gene editing company built around its ARCUS platform, which it uses for genome insertion, removal, and repair. Its pipeline includes PBGENE-HBV for chronic hepatitis B, PBGENE-DMD for Duchenne muscular dystrophy, PBGENE-3243 for mitochondrial disease, and an ARCUS-mediated targeted insertion program with iECURE for ornithine transcarbamylase deficiency. The company also has collaboration agreements tied to autoimmune and insertion-based programs.
Why it fits. Precision earns a place here because it offers a differentiated editing architecture and a more diversified disease mix than some peers, spanning infectious disease, neuromuscular disease, mitochondrial disease, and metabolic liver disease. That breadth matters in gene editing, where platform flexibility can become a strategic advantage. Still, this remains a smaller and more speculative company than the names ranked above it, which limits its standing on an investment-quality basis.
Numbers that matter. The financial picture is mixed. Revenue was $45.073 million, and year-over-year revenue growth was an eye-catching 372.724%, but profitability is still weak, with net margin at -0.9673 and operating margin at -0.8373. EBITDA was negative $37.739 million, ROE was -0.7093, and ROA was -0.1822. Trailing EPS was -$2.17, with next-year EPS estimated at -$1.915, and our data shows a forward P/E of 14.0845, which is unusual for a company still posting losses and suggests investors are already looking ahead to a materially different earnings profile.
Recent momentum. Precision’s earnings record has been volatile, with a 4-for-8 beat rate over the last eight quarters. The latest quarter on May 5, 2026 was a modest positive, with EPS of -$0.75 versus a -$0.81 estimate, a 7.4% beat, and the March 2026 quarter produced a very large positive surprise. Analysts are constructive, with 2 Buy ratings and no published Hold or Sell counts in our data, and the average target of $32 reflects how much upside the Street sees if the platform delivers.
What they do. Editas Medicine is a clinical-stage genome editing company focused on CRISPR-based medicines. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through upregulation of the LDL receptor for hyperlipidemia, and it also has programs in sickle cell disease, transfusion-dependent beta thalassemia, and other in vivo editing applications. The company also maintains a research collaboration with Juno Therapeutics in cell therapies for solid tumors, liquid tumors, and autoimmune disease.
Why it fits. Editas fits the theme because it remains one of the recognizable public names in CRISPR medicine and is trying to push editing beyond rare blood disorders into larger cardiometabolic use cases. That strategic direction matters, since the market increasingly wants to know whether gene editing can become commercially repeatable rather than remain confined to niche indications. The problem is that the company’s current financial and execution profile still looks fragile relative to stronger peers.
Numbers that matter. Editas generated $38.693 million in revenue, but profit metrics remain deeply negative. EBITDA was -$85.186 million, net margin was -2.8159, operating margin was -8.8319, gross margin was -109.2%, ROE was -3.2607, and ROA was -0.2695. Revenue declined 39.2% year over year, while trailing EPS was -$1.14 and next-year EPS is estimated at -$0.906. Those figures help explain the company’s C- quality grade despite its established position in the sector.
Recent momentum. Recent execution has been uneven. Editas has beaten estimates in only 2 of the last 8 quarters, and the latest report on May 5, 2026 missed with EPS of -$0.26 versus a -$0.2416 estimate, a -7.6% surprise. Analyst sentiment is subdued, with 1 Buy, 8 Hold, and 2 Sell ratings, which is one of the more cautious distributions on this list. The average target of $5.7778 suggests some upside if the pipeline improves, but the Street is clearly waiting for stronger proof.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. Intellia is a clinical-stage genome editing company centered on CRISPR/Cas9 with both in vivo and ex vivo ambitions. Its in vivo lead candidates include NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema, and it also has programs in immuno-oncology, autoimmune disease, and non-liver delivery through collaborations with companies including AvenCell, Kyverna, ONK, ReCode, Regeneron, SparingVision, and Rewrite. That breadth gives Intellia one of the more diversified strategic footprints in the group.
Why it fits. Intellia is one of the clearest ways to invest in the next phase of in vivo gene editing. The company sits directly in the part of the market investors care most about now: proving that editing can be delivered systemically and repeatedly beyond ex vivo blood-cell settings. Its liver-focused programs and broader delivery ambitions make it highly relevant to the current gene editing debate, even if it has not yet reached the commercial validation of the top-ranked name.
Numbers that matter. Intellia’s scale is meaningful for a development-stage biotech, with market cap in our data between $1.38 billion and $1.67 billion and revenue of $66.092 million. The company is still loss-making, with EBITDA of -$411.244 million, trailing EPS of -$3.52, and next-year EPS estimated at -$1.9119. Revenue slipped 9.5% year over year, while profitability metrics remain negative, including ROE of -0.5634, ROA of -0.3014, gross margin of -349.0%, and operating margin of -6.6808. Even so, the expected EPS improvement suggests the market sees a path toward better operating leverage.
Recent momentum. Intellia has one of the stronger earnings execution records in the group, beating estimates in 7 of the last 8 quarters. The most recent quarter on April 30, 2026 delivered EPS of -$0.81 versus a -$0.904 estimate, a 10.4% beat, following another 13.5% beat in February. Analysts are constructive but not euphoric, with 4 Buy, 6 Hold, and 1 Sell ratings, and the average target of $26.65 indicates that the Street still sees substantial value if clinical progress continues.
What they do. Verve Therapeutics is a clinical-stage company developing gene editing medicines for cardiovascular disease, a major differentiator in a field still dominated by rare-disease programs. Its pipeline includes VERVE-101 in the Heart-1 trial, VERVE-102 in the Heart-2 trial for heterozygous familial hypercholesterolemia and premature coronary artery disease, VERVE-201 targeting ANGPTL3, and VERVE-301 targeting LPA. The company also has agreements with Beam, Acuitas, Novartis, Eli Lilly, and Broad around development and enabling technologies.
Why it fits. Verve ranks highly because it is trying to apply gene editing to some of the largest potential markets in medicine rather than only to ultra-rare disorders. If in vivo editing can safely and durably lower LDL-C, ANGPTL3, or Lp(a), the commercial implications could be much broader than first-generation blood-disease therapies. That said, this is still a clinical-stage story, so the investment case depends heavily on continued validation of both efficacy and delivery.
Numbers that matter. Verve’s market cap is about $994.0 million, and revenue was $59.613 million. Revenue growth was strong at 4.79 year over year, but the company remains firmly unprofitable, with EBITDA of -$201.615 million, ROE of -0.3426, ROA of -0.1935, gross margin of -253.0%, and operating margin of -1.111. Trailing EPS was -$2.11, and next-year EPS is estimated at -$3.109, which implies analysts expect losses to widen before the model improves. Those numbers keep Verve from ranking above the two leaders despite its compelling addressable market.
Recent momentum. On execution, Verve stands out. It has beaten earnings estimates in 8 of the last 8 quarters, including 100.0% positive surprises in both November 2025 and August 2025 when EPS came in at 0 versus negative expectations. Analyst sentiment is favorable, with 3 Buy ratings and 1 Hold, and the average target of $13.125 is modestly above the last reported close in our data. One caveat is that the quote data is older than the rest of this list, so investors should treat the market snapshot as less current.
Pick #2Subscribers only
Subscribers see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This monthly list starts with a screen for US-listed gene editing stocks with market capitalizations above $500 million. From there, we rank candidates by investment quality using a blend of primary-source financial data, analyst consensus, earnings execution, profitability trends, growth metrics, and business positioning within the gene editing value chain. We also consider whether a company has commercial validation, late-stage clinical assets, or differentiated enabling technology. Because the group is still early in its lifecycle, the ranking is not based on current profits alone. Instead, it aims to balance scientific relevance with financial resilience and execution quality as the theme evolves.
